|
Post by omstem on May 24, 2017 5:51:48 GMT
I started modest and adding modestly. This is one company I have been adding at each opportunity.
1. Their PR is good. They keep the Shareholders in loop with all the developments. 2. They have fairly good cash reserves. They may do an additional funding down the lane when they have their own products to market. 3. They have already Sales People on the ground covering some products not their own, but the revenues from these are barely enough to cover the expenses. 4. The real kicker is that the sales people on the field are ready to go from day one when their own products are launched.
I strongly believe that the management has plan and they are executing it well. While they are doing it, they are not keeping the share holders in dark.
Regards.
|
|
|
Post by JHam on May 24, 2017 12:12:40 GMT
I started modest and adding modestly. This is one company I have been adding at each opportunity. 1. Their PR is good. They keep the Shareholders in loop with all the developments. 2. They have fairly good cash reserves. They may do an additional funding down the lane when they have their own products to market. 3. They have already Sales People on the ground covering some products not their own, but the revenues from these are barely enough to cover the expenses. 4. The real kicker is that the sales people on the field are ready to go from day one when their own products are launched. I strongly believe that the management has plan and they are executing it well. While they are doing it, they are not keeping the share holders in dark. Regards. Agreed on all points. I am a big fan of this management team. I also like that BEKINDA and RHB-04 for Crohn's aren't just wild shots in the dark. They have clinical data on humans (and in the case of BEKINDA it is already a therapy on the market for a different indication - but is the most prescribed drug for gastritis by GI doctors anyway). I have been adding as well and will continue to do so for now.
|
|
|
Post by JHam on May 24, 2017 14:40:13 GMT
Just added a small lot at $9.95.
|
|
|
Post by lcd on May 24, 2017 17:09:19 GMT
I added more today too at $9.98.
|
|
|
Post by JHam on May 30, 2017 14:22:12 GMT
As we await BEKINDA results, and enter the last month of 2Q, I wanted to post the PR from back in October 2016 regarding the RHB-104 protocol revisions. Early stop due to overwhelming success (which was added in October), likely won't happen due to the requirements they set. But, it is interesting that they added that new wrinkle after 219 patients (of the planned 270) had already enrolled. Not to mention adding an extension study at the same time. Between BEKINDA and the MAP trial (RHB-104), we have an event filled few months ahead of us: www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1362&PID=0&IID=5047
|
|
|
Post by JHam on May 31, 2017 5:16:54 GMT
I wonder who was selling yesterday. 2.5 x the daily average volume.
|
|
|
Post by JHam on Jun 1, 2017 14:39:00 GMT
We've entered the last month of 2Q with no news on either BEKINDA or RHB-104. Quick flippers got cold feet and are getting out, imo.
|
|
|
Post by omstem on Jun 1, 2017 15:59:06 GMT
I agree JHam.
Even though the volume looks like higher than usual, in real numbers it is still not big. It must be people worrying about the lack of news getting out and there is no real news that makes me worried. I am long and adding.
Good Luck to all.
|
|
|
Post by JHam on Jun 12, 2017 13:16:24 GMT
|
|
|
Post by JHam on Jun 12, 2017 13:32:29 GMT
From the very end of the article:
One analyst that has taken notice of the company is Swayampakula Ramakanth of H.C. Wainwright & Co., who said positive results from Bekinda’s Phase III trial could be a major catalyst. The analyst thinks there is a “high likelihood of success,” and in a recent research note maintains a Buy rating for RedHill shares with a $33 price target.
|
|
|
Post by omstem on Jun 13, 2017 2:25:03 GMT
Thank you JHam.
This is one of my favorite stocks. Not going in all-in though since I learned lessons from Ocata. But I have a fairly decent amount invested in (compared to the total value of my portfolio). The Management seems trustworthy. The pipeline products seem to be doing fine. There are plenty of catalysts and several shots at the goal. Good cash position. Good strategy. As management itself had mentioned, their not being a US based company and being a small company could be a reason why this company is not the radar of the Wall Street. It will eventually be. I am long. If and when it reaches $30+, I will cash out my original investment+taxes and let the rest ride. May not be in the near (5+ years) future, but when it becomes an acquisition target, it will be at least at half the value at which Salix was bought out for.
Good Luck to all.
|
|
|
Post by JHam on Jun 13, 2017 12:20:33 GMT
|
|
|
Post by JHam on Jun 13, 2017 18:01:17 GMT
Thank you JHam. This is one of my favorite stocks. Not going in all-in though since I learned lessons from Ocata. But I have a fairly decent amount invested in (compared to the total value of my portfolio). The Management seems trustworthy. The pipeline products seem to be doing fine. There are plenty of catalysts and several shots at the goal. Good cash position. Good strategy. As management itself had mentioned, their not being a US based company and being a small company could be a reason why this company is not the radar of the Wall Street. It will eventually be. I am long. If and when it reaches $30+, I will cash out my original investment+taxes and let the rest ride. May not be in the near (5+ years) future, but when it becomes an acquisition target, it will be at least at half the value at which Salix was bought out for. Good Luck to all. Your sentence about a good cash position and many shots on goal is exactly why I like this one. They don't need to hit a homerun on every indication they are going after (although that would obviously be nice). Making it to the market with just any one of their three programs now in P3 would bring great appreciation to this stock. As I have also mentioned before, I like that they are going after indications that are either on the market already or have had successful trials in the past. It takes the edge off the binary nature of these data readouts a little bit By the way, for those that were wondering about the Salix deal you referenced. Valeant bought Salix for $10B a couple years back. Before they were acquired however, Salix licensed RHB-106 from RedHill for $7M up front, $5M in milestones payments and a royalty on net sales. I agree that RDHL will go about licensing out their programs, if successful, but will likely will be bought out by a bigger fish in the space: www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1342&PID=0&IID=1900
|
|
|
Post by lovie350z on Jun 14, 2017 12:51:19 GMT
|
|
|
Post by JHam on Jun 14, 2017 13:09:08 GMT
Hot damn! Great news! We'll see how the market reacts today. The pps probably won't skyrocket, but BEKINDA could be a potential game changer/money maker when it is finally commercialized. I like this quote from the PR: Robert A. Silverman, MD, MS, Emergency Medicine specialist at Northwell Health and Lead Investigator of the BEKINDA® Phase III GUARD study, said: "The positive results of the Phase III GUARD study demonstrate that BEKINDA® 24 mg is beneficial in the treatment of acute gastroenteritis and gastritis and can provide patients with 24 hours of relief. Gastroenteritis is a very common illness in the U.S., with approximately 179 million cases annually. If approved by FDA, BEKINDA® may become the new standard of care helping us treat patients quickly and effectively in both the emergency and outpatient settings.”
|
|
|
Post by JHam on Jun 14, 2017 13:44:22 GMT
|
|
|
Post by tmfbmf on Jun 14, 2017 14:18:47 GMT
Jham, do you think the results are good enough for approval, or will there be another trial?
|
|
|
Post by jckrdu on Jun 14, 2017 15:11:52 GMT
Jham, do you think the results are good enough for approval, or will there be another trial? TMF - I haven't been following this one that closely (and have no position) but the below is a recent quote from the CEO on that topic... before results were announced. _________________________
www.benzinga.com/analyst-ratings/analyst-color/17/06/9565466/exclusive-redhill-biopharma-ceo-talks-steering-his-compa
It’s been proposed that with positive enough results in gastroenteritis, Bekinda could potentially bypass a second Phase 3 study and move directly for regulatory approval with the Food and Drug Administration.
“It will have to do with significance,” Ben-Asher said. “We do not know the exact number we need to achieve beyond just meeting endpoint in order to be able to file an NDA (new drug application) immediately. But the FDA has been telling us, and we have been telling the market, that if the results are strong enough we expect to file a new drug application based on this single Phase III study.”
The FDA hasn’t told RedHill the exact p-value that would qualify Bekinda to move straight to an NDA submission, but generally p<0.001 is considered “highly significant.”
|
|
|
Post by tmfbmf on Jun 14, 2017 15:37:10 GMT
Thanks Jck. I guess that explains the negative reaction to positive results.
|
|
|
Post by JHam on Jun 14, 2017 16:30:19 GMT
Thanks Jck. I guess that explains the negative reaction to positive results. In short, I don't know, but my hunch tells me it won't be enough to skip right to an NDA submission. The company has said that they need to achieve high significance in order to go right to an NDA submission, and one can only assume that would be p<0.001. Here is one thing that i am curious about. Ondansetron reduced incidence of vomiting by 50% in 9 studies in Acute Gastroenteritis. However, 7 of those studies did not include adults, and none were primarily adults. Ondansetron has been not known to work in adults. From the bottom of the PR: Adding ondansetron, the active ingredient in BEKINDA®, to the standard intravenous rehydration therapy has shown to significantly reduce the amount of vomiting in children with gastroenteritis5; however, to the best of RedHill’s knowledge, its efficacy in adult gastroenteritis patients has not been shown beneficial in a randomized clinical trial in the U.S.RedHill's study included adults, so I am curious to know what the ratio of adults:children was and how it impacted the data, and if that matters at all. I have always assumed that BEKINDA was going to be prescribed for adults as well as children.
|
|